• Pathogenetic therapy virus associated diseases in gynecological practice 
To content

Pathogenetic therapy virus associated diseases in gynecological practice 

HEALTH OF WOMAN. 2016.4(110):37–42; doi 10.15574/HW.2016.110.37 

Pathogenetic therapy virus associated diseases in gynecological practice 

Bobrytska V. V.

Kharkiv medical Academy of postgraduate education 

The aim of the study: to determine the effectiveness of the use Apigalin in complex treatment of women with clinical (including cervical dysplasia) and subclinical forms of diseases of the reproductive organs associated with the human papillomavirus (HPV) and herpes simplex virus (HSV).

The materials and methods. There were examined 70 patients with presence of clinical, subclinical and latent forms of human papillomavirus infection. The main inclusion criterion in the study group were positive results of PCR studies for the presence of HPV and HSV-2. The patients were divided into primary (n=35) and control (n=35) groups. Women of both studied groups used causal treatment according to the isolated pathogens. Patients of the main group together with a basic therapy received the drug Again 1 capsule 2 times a day, daily rate – 6 months. Patients in the control group is not received this drug. The effect of therapy in both groups was evaluated according to clinical data, Infectology studies as well as monthly conducted Cytology and colposcopy.

Results. In the main group normalization of the status of the control Infectology studies was observed already after 1 month of therapy, complete regression of symptoms was observed in 2-3 months. There was no recurrence of herpetic and papillomatous lesions, no pathological cytological results – dyskeratosis, koilocytes that are characteristic of human papillomavirus infection.

Conclusion. Apigalin can be recommended for the treatment of patients with latent and subclinical forms of HPV, in condition of continuous dynamic monitoring; as well as in complex rehabilitation therapy after electrosurgical treatment of the cervix, in the complex therapy of neoplastic conditions of the reproductive organs.

Key words: Apigalin, cervical dysplasia, HPV, HSV.


1. Borys OM. 2015. Suchasni pidkhody do kompleksnoho likuvannia ta profilaktyky retsydyviv papilomavirusnoi infektsii u zhinok reproduktyvnoho viku. Reproduktyvna endokrynolohiia:1(21).

2. Vorobiova LI. 2015. Papilomavirusna infektsiia: aktualna problema suchasnoi hinekolohii. Zdorove zhenshchyny:3(99).

3. Voloshina NN, Paschenko SN, Voloshin NA, Schurov NF, Petrova OYu. 2014. Profilaktika raka reproduktivnyih organov. Zdorove zhenschinyi: 9(95).

4. Kiselev IV, Lyashenko AA. 2008. Indinol – regulyator proliferativnyih protsessov v organah sistemyi. M, ZAO «MiraksFarma»:48.

5. Suhareva EA, Ponomareva LA, Kozlov SV. 2012. Opyit primeneniya indol-3-karbinola v lechenii dobrokachestvennyih displaziy molochnoy zhelezyi. Lechaschiy vrach (Med. nauchno-prakticheskiy zhurnal):7.

6. Tatarchuk TF, Kalugina LV. 2013. K voprosu o profilaktike i terapii gormonzavisimyih giperproliferativnyih zabolevaniy u zhenschin. Zdorove zhenschinyi 7(83):51–57.

7. Sartippour MR, Pietras R, Marquez-garban DC et al. 2006, Dec. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis. 27(12):2424–33. http://dx.doi.org/10.1093/carcin/bgl066; PMid:16785249

8. Thangapazham RL, Singh AK, Sharma A et al. 2007. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. CancerLett. 8:832–841. http://dx.doi.org/10.1016/j.canlet.2006.01.027